Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F FLT Imaging in Acute Leukemia and Myeloma (REALIZE)
NCT03633955Phase 1Recruiting
- Sponsor
- University of Oklahoma
- Start
- Jan 2023
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fluorothymidine F-18 in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute leukemia of ambiguous lineage (ALAL) and 1 more (4 cohorts), sponsored by University of Oklahoma. Primary endpoints: Proportion of 18F FLT signal uptake abnormalities with clinical pathology reports at 28 days, Proportion of 18F FLT uptake in a standard region of interest in marrow at 28 days and 1 more. Started Jan 2023; status: recruiting.
02
Drugs
fluorothymidine F-18
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)acute leukemia of ambiguous lineage (ALAL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03633955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03633955.